Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Harrison Robert Gardner, Chief Information Officer of Sera Prognostics NASDAQ:SERA, sold 2,000 shares of Class A Common Stock on October 7, 2025, for $6360. The company, which has seen a notable 10% return over the past week, currently maintains a market capitalization of $120 million and holds more cash than debt on its balance sheet.
The shares were sold at a weighted average price of $3.18, with individual sales prices ranging from $3.04 to $3.28. Following the transaction, Gardner directly owns 97,932 shares of Sera Prognostics . According to InvestingPro analysis, the stock is currently trading near its Fair Value, with 8 additional key insights available to subscribers, including detailed profitability and growth metrics.
The sale was executed under a Rule 10b5-1 trading plan adopted on May 21, 2025. The company’s financial health score stands at "FAIR" based on InvestingPro’s comprehensive analysis, which includes detailed metrics available in the Pro Research Report.
In other recent news, Sera Prognostics reported its second quarter 2025 earnings, revealing a notable earnings per share (EPS) of -$0.16, which surpassed the forecasted -$0.23. Despite this positive earnings surprise, the company’s revenue fell significantly short of expectations, recording $17,000 against a forecast of $100,000. These earnings results reflect recent developments at Sera Prognostics. In another update, Sera Prognostics appointed Dr. Tiffany Inglis as Chief Medical Officer. Dr. Inglis brings experience from her previous roles at Elevance Health and Carelon Health, where she focused on women’s and children’s health programs. She will now lead Sera’s clinical operations as the company aims to expand the adoption of its PreTRM Test. These updates highlight the ongoing strategic and operational changes at the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.